G. Fur

发表

SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome

C. Wermuth, P. Soubrié, R. Boigegrain, 2005, Psychopharmacology.

Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747

P. Casellas, G. Fur, J. Breliere, 1994, Journal of Neuroimmunology.

An Amino-terminal Variant of the Central Cannabinoid Receptor Resulting from Alternative Splicing (*)

M. Kaghad, P. Ferrara, D. Caput, 1995, The Journal of Biological Chemistry.

Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice

P. Soubrié, M. Poncelet, J. Souilhac, 1995, Pharmacology Biochemistry and Behavior.

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and Human Vasopressin Via Receptors

Ala, C. S. Gal, S., 2022 .

Immunopharmacological profile of SR 31747: In vitro and in vivo studies on humoral and cellular responses

P. Casellas, G. Fur, J. Breliere, 1994, Journal of Neuroimmunology.

The Cannabinoid CB 1 Receptor Antagonist Rimonabant ( SR 141716 ) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3 T 3 F 442 A Preadipocytes

B. Scatton, F. Oury-Donat, G. Fur, 2006 .

In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum

G. Fur, J. Maffrand, M. Rinaldi-Carmona, 1998, British journal of pharmacology.

Evidence for the presence of β3-adrenergic receptor mRNA in the human brain

P. Ferrara, D. Caput, G. Fur, 1995 .

Administration of amyloid β-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound

P. Soubrié, J. Kan, J. Terranova, 1996, Neuroscience Letters.

Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors

P. Soubrié, M. Thiébot, M. Poncelet, 1997, Psychopharmacology.

HISTORY OF THE DEVELOPMENT AND CLINICAL USE OF CB1 RECEPTOR INVERSE AGONISTS/ANTAGONISTS

G. Fur, 2008 .

Autoradiographic localization of peripheral benzodiazepine binding sites in the cat brain with [3H]PK 11195

M. Desban, J. Bénavidès, G. Fur, 1984, Brain Research Bulletin.

Effects of SR 49059, a non‐peptide antagonist of vasopressin V1a receptors, on vasopressin‐induced coronary vasoconstriction in conscious rabbits

C. S. Gal, G. Fur, J. Maffrand, 1995, Fundamental & clinical pharmacology.

Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates

P. Soubrié, R. Steinberg, G. Fur, 1993, Neuroscience.

Functional identification of rat atypical β‐adrenoceptors by the first β3‐selective antagonists, aryloxypropanolaminotetralins

G. Fur, R. Cecchi, T. Croci, 1996 .

Pharmacological profile and chemical synthesis of SR 48968, a non-peptide antagonist of the neurokinin A (NK2) receptor

G. Fur, G. Néliat, C. Advenier, 1993 .

Platelet MAO activity in clinical subtypes of depression and DST suppression

C. Benkelfat, H. Lôo, G. Fur, 1987, Acta psychiatrica Scandinavica.

Biochemical and electrophysiological properties of SR 57746A, a new, potent 5‐HT1A receptor agonist

P. Soubrié, M. Hamon, R. Steinberg, 1993, Fundamental & clinical pharmacology.

Evidence for a tachykinin/cholinergic mediation of D1, agonist-induced turning in mice

P. Soubrié, M. Poncelet, J. Souilhac, 1996, Neuroscience Letters.

SR 48968, a neurokinin A (NK2) receptor antagonist

P. Soubrié, M. Poncelet, G. Fur, 1992, Regulatory Peptides.

carboxamide ] , a New Potent and Selective Antagonist of the CB 1 Cannabinoid Receptor : Biochemical and Pharmacological Characterization

P. Soubrié, M. Poncelet, G. Fur, 2004 .

Reduction of opioid dependence by the CB1 antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction

B. Roques, E. Tzavara, G. Fur, 2001, British journal of pharmacology.

SR 140333, a Novel, Selective, and Potent Nonpeptide Antagonist of the NK1 Tachykinin Receptor: Characterization on the U373MG Cell Line

P. Soubrié, A. Bordey, F. Oury-Donat, 1994, Journal of neurochemistry.

Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK receptor stimulation

R. Steinberg, G. Fur, A. Thirion, 1998 .

Social olfactory recognition in rodents: deterioration with age, cerebral ischaemia and septal lesion

P. Soubrié, P. Worms, J. Terranova, 1994, Behavioural pharmacology.

The CCKA Receptor Antagonist SR 27897 Differentially Influences the Activity of A9 and A10 Dopaminergic Neurons in the Rat

P. Soubrié, D. Gully, C. Gueudet, 1994, Annals of the New York Academy of Sciences.

Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle.

H. Lôo, B. Scatton, G. Fur, 1985, Neuropsychobiology.

Effects of the σ receptor ligand SR 31742A on neurotensin biosynthesis in rat basal ganglia

P. Soubrié, G. Fur, P. Keane, 1995, Synapse.

Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist

P. Soubrié, D. Gully, M. Poncelet, 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

Are antihistamines sedative via a blockade of brain H1 receptors?

G. Fur, A. Uzan, Christiane Maloouris, 1979, The Journal of pharmacy and pharmacology.

SR 27417, a highly potent, selective and long-acting antagonist of the PAF receptor

G. Fur, J. Herbert, J. Maffrand, 1992 .

Dihydro-imidazolone derivatives as angiotensin II receptor antagonists: chiral effect on the activity

G. Fur, D. Nisato, J. Breliere, 1994 .

Labelling of peripheral-type benzodiazepine binding sites in human brain with [3H]PK 11195: Anatomical and subcellular distribution

A. Basbaum, G. Fur, A. Uzan, 1987, Brain Research Bulletin.

Role of tachykinins in castor oil diarrhoea in rats

G. Fur, J. Maffrand, T. Croci, 1997, British journal of pharmacology.

Effects of SR140333, a selective non‐peptide NK1 receptor antagonist, on trigemino‐thalamic nociceptive pathways in the rat

P. Soubrié, C. Gueudet, J. Michaud, 1998, Fundamental & clinical pharmacology.

Electrophysiological, behavioural and biochemical evidence for activation of brain noradrenergic systems following neurokinin receptor stimulation

P. Soubrié, A. Hayar, R. Steinberg, 1996, Neuroscience.

Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors

P. Soubrié, C. Gueudet, J. Souilhac, 1994, Neuropharmacology.

Turning behavior induced in mice by a neurokinin A receptor agonist: Stereoselective blockade by SR 48968, a non-peptide receptor antagonist

P. Soubrié, M. Poncelet, C. Gueudet, 1993, Neuroscience Letters.

Involvement of tachykinins in the bronchospasm induced by chemicals in the guinea-pig. Inhibition by SR48968

G. Fur, J. Breliere, C. Advenier, 1994, Neuropeptides.

Evidence for Modulation of DoDamine‐neuronal Function by Tachykinin NK3 Receptor Stimulation in Gerbil Mesencephalic Cell Cultures

P. Soubrié, G. Fur, P. Carayon, 1996, The European journal of neuroscience.

2 R , 6 S )-2 , 6-dimethylpiperidinyl ] methyl } phenyl )-N-isopropyl-N-methylpropanamide Hydrochloride ] , a New Nonpeptide Antagonist of the Bradykinin B 1 Receptor : Biochemical and Pharmacological Characterization

P. Soubrié, M. Poncelet, G. Fur, 2004 .

Characterization of the effect of SR48692 on inositol monophosphate, cyclic GMP and cyclic AMP responses linked to neurotensin receptor activation in neuronal and non‐neuronal cells

P. Soubrié, D. Gully, F. Oury-Donat, 1995, British journal of pharmacology.

Structural Features of the Central Cannabinoid CB1 Receptor Involved in the Binding of the Specific CB1 Antagonist SR 141716A (*)

Pascual Ferrara, David Shire, M. Kaghad, 1996, The Journal of Biological Chemistry.

Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study

P. Soubrié, J. Michaud, G. Fur, 1997, Neuroscience.

Both the Immunosuppressant SR31747 and the Antiestrogen Tamoxifen Bind to an Emopamil-Insensitive Site of Mammalian Δ8-Δ7 Sterol Isomerase

Pascual Ferrara, Raymond Paul, Pierre Casellas, 1998 .

Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia

P. Soubrié, P. Ferrara, D. Caput, 2002, Brain Research.

Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats

P. Soubrié, D. Gully, M. Poncelet, 1994, Psychopharmacology.

Stimulation by neurotensin of (3H)5-hydroxytryptamine (5HT) release from rat frontal cortex slices

P. Soubrié, M. Héaulme, R. Leyris, 1998, Neuropeptides.

Neuropharmacological profile of non‐peptide neurotensin antagonists

P. Soubrié, D. Gully, F. Jeanjean, 1995, Fundamental & clinical pharmacology.

FM24: A long lasting blocker of rat liver β-adrenoreceptors

J. Hanoune, G. Fur, A. Uzan, 1979 .

Decrease in [3H]ouabain binding sites in heart and brain from spontaneously hypertensive rats

G. Fur, A. Uzan, M. Corgier, 1981, Experientia.

Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders

S. Stahl, G. Griebel, J. Stemmelin, 2008, Neuropsychopharmacology.

Stimulation of Cannabinoid Receptor CB1 Induces krox-24 Expression in Human Astrocytoma Cells (*)

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1995, The Journal of Biological Chemistry.

Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation.

S. Galiègue, P. Casellas, G. Fur, 1998, Blood.

Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal [3H]dopamine release evoked by KC1 versus electrical depolarization

Michel Heaulme, Roger Leyris, Gérard Le Fur, 1997, Neuropharmacology.

The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes

P. Soubrié, J. Terranova, G. Fur, 1994, British journal of pharmacology.

Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A

P. Soubrié, M. Poncelet, C. Gueudet, 1993, Neuropharmacology.

Blockade of CRF1 or V1b receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression

G. Griebel, P. Soubrié, J. Stemmelin, 2004, Molecular Psychiatry.

Labelling of “Peripheral‐Type” Benzodiazepine Binding Sites in the Rat Brain By Using [3H]PK 11195, an Isoquinoline Carboxamide Derivative: Kinetic Studies and Autoradiographic Localization

G. Fur, A. Uzan, C. Malgouris, 1983, Journal of neurochemistry.

BEHAVIOURAL AND BIOCHEMICAL EVIDENCE FOR ACTIVATION OF BRAIN NORADRENERGIC SYSTEMS FOLLOWING NEUROKININ NK 3 RECEPTOR STIMULATION

P. Soubrié, A. Hayar, R. Steinberg, 1996 .

Role of Peripheral Benzodiazepine Receptors in Mitochondrial, Cellular, and Cardiac Damage Induced by Oxidative Stress and Ischemia-Reperfusion

G. Fur, J. Herbert, T. Sulpice, 2003, Journal of Pharmacology and Experimental Therapeutics.

Tissue levels and displacement of in vivo labelled β-adrenergic receptors by FM 24, an irreversible or slowly dissociable β-blocker

G. Fur, A. Uzan, C. Rougeot, 1980 .

Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents

J. Simiand, P. Soubrié, M. Poncelet, 2005, Journal of Neural Transmission / General Section JNT.

Development of tetrazole bioisosteres in angiotensin II antagonists

G. Fur, D. Nisato, J. Breliere, 1994 .

SR 48968, a neurokinin A (NK2) receptor antagonist

G. Fur, J. Breliere, C. Advenier, 1992, Regulatory Peptides.

Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons

P. Soubrié, J. Michaud, G. Fur, 1998, Neuroscience.

Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain

P. Soubrié, G. Fur, N. Fréchin, 1999, The European journal of neuroscience.

Expression and presence of septal neurokinin‐2 receptors controlling hippocampal acetylcholine release during sensory stimulation in rat

P. Soubrié, R. Steinberg, F. Oury-Donat, 1998, The European journal of neuroscience.

Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors

P. Soubrié, J. Michaud, J. Terranova, 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

S. Galiègue, P. Casellas, G. Fur, 1995, European journal of biochemistry.

Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists

P. Soubrié, D. Gully, M. Poncelet, 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

Cyclopentanespiro-3H-dihydro-pyrimidinones as Angiotensin II AT1 receptor antagonists

G. Fur, D. Nisato, J. Breliere, 1994 .

Biochemical evidence that 2-phenyl-4[2-(4-piperidinyl) ethyl]quinoline, a quinoline derivative with pure anticonflict properties, is a partial agonist of benzodiazepine receptors

G. Fur, A. Uzan, C. Malgouris, 1984, Neuropharmacology.

Identification of binding sites for SR 46349B, a 5-hydroxytryptamine2 receptor antagonist, in rodent brain.

G. Fur, M. Rinaldi-Carmona, C. Congy, 1994, Life sciences.

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Cannabinoid-receptor expression in human leukocytes.

P. Casellas, G. Fur, D. Shire, 1993, European journal of biochemistry.

Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1998, The Journal of pharmacology and experimental therapeutics.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C. S. Gal, G. Fur, L. Bankir, 1996, The Journal of clinical investigation.

Molecular cloning and chromosomal localization of a human peripheral-type benzodiazepine receptor.

M. Mattei, M. Kaghad, X. Dumont, 1991, European journal of biochemistry.

Expression and pharmacological characterization of the human peripheral-type benzodiazepine receptor in yeast.

P. Ferrara, D. Caput, G. Fur, 1991, European journal of pharmacology.

Effect of SR 59026A, a new 5‐HT1A receptor agonist, on sexual activity in male rats

G. Fur, M. Arnone, P. Keane, 1995, Behavioural pharmacology.

Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

P. Soubrié, D. Gully, M. Canton, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

P. Ferrara, D. Caput, G. Fur, 1996, Biochimica et biophysica acta.

PK 11195, an antagonist of peripheral benzodiazepine receptors, reduces ventricular arrhythmias during myocardial ischemia and reperfusion in the dog.

G. Fur, G. Bouétard, G. Le Fur, 1985, European journal of pharmacology.

In vivo labelling in several rat tissues of 'peripheral type' benzodiazepine binding sites.

J. Bénavidès, G. Fur, P. Rufat, 1984, European journal of pharmacology.

SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.

P. Casellas, G. Fur, M. Rinaldi-Carmona, 1999, The Journal of pharmacology and experimental therapeutics.

Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.

P. Soubrié, G. Fur, G. Le Fur, 1996, Life sciences.

Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.

P. Ferrara, G. Fur, D. Shire, 1999, European journal of pharmacology.

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.

P. Soubrié, G. Fur, M. Rinaldi-Carmona, 1996, Life sciences.

Serotonin: Change in Plasma‐free Level and Urinary Excretion after LM 5008 and Reserpine

G. Fur, A. Uzan, F. Imbault, 1979, Headache.

SR 140333, a non-peptide antagonist of substance-P (NK1) receptor

P. Soubrié, G. Fur, J. Breliere, 1993, Neuropeptides.

Up-regulation of 5-HT2 receptors in the rat brain by repeated administration of SR 46349B, a selective 5-HT2 receptor antagonist.

J. Simiand, P. Soubrié, P. Casellas, 1993, European journal of pharmacology.

Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.

J. Simiand, P. Soubrié, F. Oury-Donat, 1993, Molecular pharmacology.